IgG3 collaborates with IgG1 and IgA to recruit effector function in RV144 vaccinees

While the RV144 HIV vaccine trial led to moderately reduced risk of HIV acquisition, emerging data from the HVTN702 trial point to the critical need to reexamine RV144-based correlates of reduced risk of protection. While in RV144, the induction of V2-binding, non-IgA, IgG3 antibody responses with n...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:JCI Insight
Auteurs principaux: Fischinger, Stephanie, Dolatshahi, Sepideh, Jennewein, Madeleine F., Rerks-Ngarm, Supachai, Pitisuttithum, Punnee, Nitayaphan, Sorachai, Michael, Nelson, Vasan, Sandhya, Ackerman, Margaret E., Streeck, Hendrik, Alter, Galit
Format: Artigo
Langue:Inglês
Publié: American Society for Clinical Investigation 2020
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7710302/
https://ncbi.nlm.nih.gov/pubmed/33031099
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.140925
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires